| Title |
Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus
|
|---|---|
| Published in |
Journal of NeuroVirology, May 2016
|
| DOI | 10.1007/s13365-016-0449-0 |
| Pubmed ID | |
| Authors |
Milton H. Werner, DeRen Huang |
| Abstract |
Sixty-three natalizumab-treated patients with relapsing multiple sclerosis were screened for JC polyomavirus (JCV) viruria. Urinary-positive patients were longitudinally sampled for up to 24 weeks. Using methods that distinguish encapsidated virus from naked viral DNA, 17.5 % of patients were found to excrete virus, consistent with the prevalence of urinary excretion in the general population. Unexpectedly, urinary excretion was predominantly seen (>73 %) in patients with high JC antibody index (≥2.0). Active JCV infection, therefore, tends to occur in natalizumab patients that carry a high risk factor for the development of disease, directly linking JC infection to the risk factors for PML development. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
| Science communicators (journalists, bloggers, editors) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 37 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 24% |
| Student > Bachelor | 7 | 19% |
| Student > Master | 5 | 14% |
| Other | 3 | 8% |
| Student > Postgraduate | 3 | 8% |
| Other | 5 | 14% |
| Unknown | 5 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 38% |
| Agricultural and Biological Sciences | 5 | 14% |
| Neuroscience | 4 | 11% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Immunology and Microbiology | 2 | 5% |
| Other | 4 | 11% |
| Unknown | 6 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 May 2016.
All research outputs
#2,943,693
of 22,873,031 outputs
Outputs from Journal of NeuroVirology
#61
of 928 outputs
Outputs of similar age
#53,111
of 334,143 outputs
Outputs of similar age from Journal of NeuroVirology
#2
of 21 outputs
Altmetric has tracked 22,873,031 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 928 research outputs from this source. They receive a mean Attention Score of 4.2. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 334,143 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.